We are live on
!
Find out more
MP
MFN Partners Portfolio holdings
AUM
$4.77B
1-Year Est. Return
72.29%
This Fund
S&P 500
This Quarter
Est. Return
-7.27%
1 Year Est. Return
+72.29%
3 Year Est. Return
+200.41%
5 Year Est. Return
+244.77%
10 Year Est. Return
–
AUM
$669M
AUM Growth
+$39M
(+6.2%)
Cap. Flow
+$115M
Cap. Flow
% of AUM
17.12%
Top 10 Holdings %
Top 10 Hldgs %
98.01%
Holding
17
New
–
Increased
5
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$81.5M |
| 2 |
Liberty Global Class C
LBTYK
|
+$61.8M |
| 3 |
Cheniere Energy
LNG
|
+$19.2M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
+$14.6M |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$8.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$35.6M |
| 2 |
XPO
XPO
|
+$14.3M |
| 3 |
Takeda Pharmaceutical
TAK
|
+$13.9M |
| 4 |
Navient
NAVI
|
+$3.33M |
| 5 |
GTT
GTT Communications, Inc.
GTT
|
+$3.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.8% |
| 2 | Communication Services | 23.22% |
| 3 | Energy | 14.85% |
| 4 | Industrials | 7.49% |
| 5 | Utilities | 4.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $236M | 35.22% |
1,400,101
+500,000
| +56% | +$81.5M |
|
2
Fox Class A
FOXA
$24.8B
| $74.7M | 11.17% |
2,369,331
| – | – |
|
|
3
Liberty Global Class C
LBTYK
$3.5B
| $71.4M | 10.67% |
3,000,000
+2,374,442
| +380% | +$61.8M |
|
|
4
Cheniere Energy
LNG
$54.2B
| $66.2M | 9.9% |
1,050,000
+300,000
| +40% | +$19.2M |
|
|
5
Ironwood Pharmaceuticals
IRWD
$586M
| $55.3M | 8.26% |
6,439,541
+1,500,000
| +30% | +$14.6M |
|
|
6
XPO
XPO
$23.4B
| $50.1M | 7.49% |
2,023,976
-618,570
| -23% | -$14.3M |
|
|
PXD
7
DELISTED
Pioneer Natural Resource Co.
PXD
| $33.1M | 4.95% |
263,500
+63,500
| +32% | +$8.4M |
|
8
PG&E
PCG
$39B
| $28M | 4.19% |
2,800,000
| – | – |
|
|
FG
9
DELISTED
FGL Holdings Ordinary Shares
FG
| $23.1M | 3.46% |
2,896,186
-103,814
| -3% | -$826K |
|
10
Cyclerion Therapeutics
CYCN
$15.2M
| $18M | 2.7% |
74,394
| – | – |
|
|
GTT
11
DELISTED
GTT Communications, Inc.
GTT
| $9.24M | 1.38% |
981,143
-268,857
| -22% | -$3.02M |
|
12
Evolus
EOLS
$397M
| $1.87M | 0.28% |
120,000
| – | – |
|
13
Aclaris Therapeutics
ACRS
$715M
| $1.62M | 0.24% |
1,500,000
| – | – |
|
|
RVNC
14
DELISTED
Revance Therapeutics, Inc.
RVNC
| $598K | 0.09% |
46,000
| – | – |
|
|
15
Goldman Sachs
GS
$289B
| – | – |
-173,811
| Closed | -$35.6M |
|
|
16
Navient
NAVI
$819M
| – | – |
-244,300
| Closed | -$3.33M |
|
|
17
Takeda Pharmaceutical
TAK
$56.7B
| – | – |
-785,000
| Closed | -$13.9M |
|
Similar funds
WAM
MF
CA
RC
GAM
JCM
SAMU
MFN Partners's Q3 2019 Portfolio in Review
As of Q3 2019, MFN Partners held 17 positions worth $669M, up 6.2% from $630M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
MFN Partners deployed $115M of net new capital in Q3 2019, adding to 5 existing holdings.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 38% a quarter earlier, followed by Communication Services and Energy.
On the sell side, the largest reduction was XPO, an estimated $14.3M trimmed.
- MFN Partners added most to Allergan plc in Q3 2019, an estimated $81.5M increase.
- MFN Partners's biggest Q3 2019 reduction was XPO, cutting an estimated $14.3M.
- MFN Partners fully exited Goldman Sachs in Q3 2019, selling an estimated $35.6M.
- MFN Partners's ten largest holdings make up 98% of its $669M portfolio in Q3 2019.
- MFN Partners opened 0 new positions and closed 3 in Q3 2019.
- MFN Partners's portfolio value rose 6.2% quarter-over-quarter to $669M.
Based on MFN Partners's 13F filing for Q3 2019, filed 14 Nov 2019.